What is Helaina?
Founded in 2019 and headquartered in New York, Helaina is a biotechnology startup dedicated to supporting parents and newborns through the development of alternative breast milk proteins. By utilizing precision fermentation, the company creates bioactive proteins that mimic the functional benefits of human milk, addressing critical gaps in infant nutrition. Helaina operates at the intersection of food science and health technology, aiming to provide high-quality, accessible nutritional solutions that prioritize infant health and development. Its market position is defined by its commitment to scientific rigor and its ability to attract high-profile venture capital backing, signaling a strong competitive advantage in the burgeoning field of synthetic biology and sustainable food production.
How much funding has Helaina raised?
Helaina has raised a total of $65M across 2 funding rounds:
Series A
$20M
Series B
$45M
Series A (2021): $20M with participation from Plum Alley, Spark Capital, Siam Capital Group, and Primary Venture Partners
Series B (2024): $45M led by Spark Capital, Avidity Partners, Ingeborg Investments, and Barrel Ventures
Key Investors in Helaina
Spark Capital
Spark Capital is a multi-stage venture firm that invests in products and creators across various sectors, known for backing transformative companies like Twitter and Coinbase.
Ingeborg Investments
Ingeborg Investments is a mission-driven firm dedicated to backing exceptional female founders and leaders, focusing on startups that empower women in health and financial security.
Barrel Ventures
Barrel Ventures is a Midwest-based seed fund that specializes in innovative food systems, sustainable ingredients, and supply chain efficiency.
What's next for Helaina?
With the successful closure of its latest financing round, Helaina is well-positioned to scale its operations and navigate the complex regulatory landscape inherent in the infant nutrition sector. The strategic focus will likely shift toward optimizing manufacturing processes to ensure consistent, large-scale production of its precision-fermented proteins. Furthermore, the company is expected to deepen its engagement with industry stakeholders and health professionals to validate the efficacy and safety of its products. As Helaina continues to mature, the focus will remain on achieving commercial viability and establishing a sustainable supply chain that can meet the growing global demand for innovative, science-backed nutritional alternatives. The company's ability to maintain its momentum will be critical as it seeks to disrupt traditional market incumbents and set new standards for infant health.
See full Helaina company page
